Related Experiment Video
Updated: Aug 4, 2026

Creation of Reversible Cholestatic Rat Model
Published on: May 22, 2011
Acute cholestatic hepatitis probably associated with risperidone
Francisca Llinares Tello1, Carmen Hernández Prats, Nuria Bosacoma Ros
1Alicante University General Hospital, Spain. paquillinares@eresmas.com
Objective:
Risperidone is an atypical neuroleptic drug widely used due to the lower incidence and severity of hepatic adverse effects in comparison to phenothiazines. Although idiosyncratic reversible hepatotoxicity may occur in association with risperidone, the interaction with fluoxetine might increase the risk of toxic liver injury in a vulnerable patient.
Methods And Results:
We present a case of acute cholestatic hepatitis probably associated with the use of risperidone after only a few days of therapy in a patient also treated with fluoxetine. The patient, a 64-year-old male, developed a rapid increase in liver enzymes after starting treatment with only four doses of risperidone 2 mg/day.
Conclusions:
We recommend obtaining baseline liver function tests before starting risperidone and regular monitoring to screen patients for liver damage during therapy whenever a patient is also receiving fluoxetine.
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Toxicity: Risk factors
Hepatitis
Cholecystitis
Chronic Pancreatitis II: Pathophysiology

